Double-blind study of milacemide in hospitalized therapy-resistant patients with epilepsy

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Neurology

Background:

• Epilepsy remains a significant neurological disorder requiring novel therapeutic strategies.
• Milacemide, a glycine prodrug, is designed to cross the blood-brain barrier, offering potential for central nervous system (CNS) effects.
• Existing antiepileptic treatments may have limitations in efficacy or tolerability for some patient populations.

Purpose of the Study:

• To evaluate the antiepileptic efficacy and tolerability of milacemide in patients with epilepsy.
• To compare the effects of milacemide versus placebo in add-on therapy for epilepsy management.
• To investigate potential efficacy in specific patient subgroups, including younger individuals.

Main Methods:

• A double-blind, placebo-controlled trial involving 60 patients with epilepsy.
• Patients received either milacemide or placebo as an adjunct to their existing partly effective medication.
• Seizure frequency was monitored, and the ratio of seizure frequency during the trial to baseline (RSF) was calculated.

Main Results:

• A higher proportion of patients in the milacemide group (9/29) achieved an RSF < 0.7 compared to the placebo group (2/29).
• One patient with myoclonus epilepsy showed dramatic improvement with milacemide treatment.
• A statistically significant reduction in seizure frequency was observed in patients aged ≤ 25 years treated with milacemide.

Conclusions:

• Milacemide demonstrated a trend towards antiepileptic efficacy, warranting further investigation.
• The drug was well tolerated in the study population.
• Milacemide shows promise, particularly in younger patients with epilepsy, suggesting a need for larger-scale clinical trials.